NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-08-31
Reading UHS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Warn: Primary pillar under pressure — Maintain EPS near $23.4 per share in fiscal 2026: FY26 EPS guidance mid $22.97 vs target $23.4; low $22.28 vs trip < $21.5.
UHS grows revenue about 6% a year to $18.6 billion in 2026. EPS stays strong near $23.4 per share. The company manages capital spending near $1 billion. New care models and payment increases help growth.
Legal issues and executive departures may hurt management and reputation. Revenue growth could slow below 6%. Capital spending might rise above forecast. These risks could weaken earnings.
The price is about 52% below our fair value near $341. Analysts expect about 6% revenue growth. Our fair value is well above the Street median of $204.
Breaks if: capex exceeds $1.1B in FY26
Breaks if: EPS falls below $21.5 in FY26
Breaks if: major legal rulings or executive departures hurt management
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on maintaining growth in revenue and earnings. The current thesis state is intact, supported by strong recent financial results, although management has shown volatility in execution.
The market appears to price UHS as cheap compared to its peers, with an expectations gap indicating that investors may not fully anticipate future growth. The valuation is justified, reflecting a low fragility tier in the current market regime.
Fundamentals are likely to continue improving, as management has consistently prioritized revenue and earnings growth. However, there is a near-term risk of missing expectations, given the company's recent history of misses.
The long-term thesis hinges on management's ability to raise guidance in the next quarter and the performance of sector bellwethers like HCA and THC. Additionally, broader economic conditions, particularly job growth, will influence UHS's performance.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company beat earnings expectations recently. This supports revenue and growth. However, UHS cut its 2026 forecast due to Medicaid uncertainty. This threatens revenue growth.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: revenue falls below $17.3B in FY26
UHS aims to increase its revenue forecast for the fiscal year 2026.
Overall, UHS maintains a solid position in its industry, but it must navigate management volatility and external economic pressures. Not investment advice.
